Shots:

• The expanded label approval is based on P-III KEYNOTE-189 study results assessing Alimta + pembrolizumab + Pt-based CT vs Alimta + Pt-based CT +PBO in 616 patients with mnon-sq NSCLC- regardless of PD-L1 expression
• P-III KEYNOTE-189 results: mPFS (8.8 vs 4.9 mos.); ORR (48% vs 19%); CR (0.5% vs 0.5%); PR (47% vs 18%); mDOR (11.2 vs 7.8 mos.); mOS (NR vs 11.3mos.)
• Alimta is a combination therapy and has received its FDA approval in Jun-2018 for 1L mnon-sq NSCLC in combination with pembrolizumab and carboplatin

Ref: Eli Lilly | Image: Eli Lilly